NTLA

Intellia Therapeutics, Inc. NGM · NTLA

$11.13 -0.34 (-2.96%)

Deep pullback · -2.41σ Hot zone

+ Compare Open in Sniper

Mkt cap $1.6B

P/E —

Day $11.07 – $11.46

52wk $10.91 – $18.48

Avg vol 7.0M

Beta 1.77

Div yld —

Next earnings 2026-08-06

Quick read

At a glance

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

NTLA last traded at $11.13, down 3.0% on the day; that's in the lower part of its 52-week range ($10.91–$18.48). Right now it's stretched well below its recent average — historically the kind of washed-out level where bounces tend to start.

The next scheduled earnings report (2026-08-06) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is stretched well below its normal range — a standard stretch that often pulls back toward normal.

Long —

Setup score 22 / 100

Price is stretched well below its normal range — a standard stretch that often pulls back toward normal.

ℹ️ Stretched (KC2): stop is set a little wider to avoid a whipsaw, so the reward/risk reads a bit lower by design.

· KC2 lower stretch — standard mean-reversion tier
· Counter-trend long in strong downtrend

Technical read: KC2 lower, -2.28 ATR from EMA21 · no notable pattern

What it means: Price is stretched well below its normal range — a standard stretch that often pulls back toward normal. The trigger bar shows no standout candle signal yet.

Score split: chart signals 22 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 22 pts

Cycle position 22

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 16 / 100

Price is sitting close to its normal range — not meaningfully overheated yet.

· Aligned with strong downtrend (strong tailwind)

Technical read: below KC1 upper, -2.28 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 16 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 32), the trend is strong (ADX 30), and trading is light at 0.3× normal volume. On the business side, revenue is shrinking 10% year over year and the business keeps about -348 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI

0–100 · <30 oversold

Trend strength · ADX

>25 = strong trend

Volume vs avg

0.32×

1× = average

Stretch from avg

-2.3 ATR

− below · + above

Zone touches

tests of this zone

Suggested hold

4–45

bars (≈ days)

Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth

-9.5%

year over year

Free-cash-flow margin

-347.6%

cash kept per $ of sales

Debt / equity

0.13

lower = less leveraged

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Unknown Accounting: Weak

Fair-value range

$1.45 – $1.45

Accounting quality Weak

✓ More cash than debt
✓ Quick ratio 3.71 (antifragile)
✓ Current ratio 5.08 (antifragile)
✓ Debt/equity 0.25 (antifragile)

⚠ Negative retained earnings
⚠ Stock comp 119% of revenue (heavy dilution)

Key statistics

All statistics →

NTLA is a $1.6 billion company, it moves harder than the market (beta 1.8), and the stock is trading near the bottom of its 52-week range.

Market cap $1.6B

P/E ttm —

Beta 1.77

52w range $10.91 – $18.48

Avg volume 7.0M

Dividend yield —

Sector Healthcare

Next earnings 2026-08-06

52-week range · today's price

$10.91$18.48

More on NTLA

Options idea

See more →

CALL $11 2026-08-21

$1.13

PUT $11 2026-08-21

$0.95

Earnings

See more →

Last reported: 2026-05-11
EPS (act / est): -0.81 / -0.90
Surprise: +9.8%
Next report: 2026-08-06

About

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vi…